Liver Transplantation in the Treatment of Liver Cancer
The treatment of choice for hepatic malignancy has been total surgical removal of tumor(s). Ex-tensive liver resection such as right and left trisegmentectomies can now be performed with an operative mortality of less than 5% . Five-year survival of primary liver malignancy after subtotal liver resection has been as high as 46% . On the other hand, the prognosis of liver cancer which cannot be treated with the conventional technique of subtotal liver resection because of extensive hepatic involvement of tumors or coexisting nonneoplastic liver disorders has been quite poor. Total hepatectomy with hepatic replacement (orthotopic liver transplantation) is, at least in concept, an ideal approach for the “unresectable” liver cancer.
KeywordsLiver Transplantation Orthotopic Liver Transplantation Biliary Atresia Bile Duct Cancer Bile Duct Carcinoma
Unable to display preview. Download preview PDF.
- 2.Starzl TE (with the assistance of Putnam CW) (1969) Experience in hepatic transplantation. WB Saunders Company, PhiladelphiaGoogle Scholar
- 8.Calne RY (ed) (1983) Liver transplantation: The Cambridge/King’s College Hospital Experience. Grune and Stratton, London/New YorkGoogle Scholar
- 10.Edmondson HA (1956) Differential diagnosis of tumors and tumor-like lesions of the liver in infancy and childhood. Am J Dis Child 91:168–186Google Scholar
- 11.Peters RL (1975) Pathology of hepatocellular carcinoma. In: Okuda K, Peters R (eds) Hepatocellular carcinoma. Wiley, New York, pp 107–168Google Scholar
- 15.Dail DH, Liebow AA (1975) Intravascular bronchioloalveolar tumor. Am J Pathol 78:61aGoogle Scholar
- 20.Alexander P, Eccles SA (1983) Host mediated mechanisms in the elimination of circulating cancer cells. Symp Foundam Cancer Res 36:293–308Google Scholar
- 21.Hanna N (1983) Role of natural killer cells in host defense against cancer metastasis. Symp Foundam Cancer Res 36: 309–320Google Scholar
- 22.Milas L, Peters TJ (1983) Conditioning of tissues for metastasis formation by radiation and cytotoxic drugs. Symp Foundam Cancer Res 36:321–336Google Scholar